Ann: Appendix 4E & Annual Report 30 June 2018, page-2

So, focusing on the second-half:

They came in with JH2018 Revenue less than 1% lower than pcp and the EBITDA margin was 29.3% (only modestly lower than pcp's 30.1%)

Given all the anecdotal evidence and the broker chatter about how weak demand for IVF services have been recently, to come in with second-half EBITDA ex-Australia being down just 3% is a bit of a statement about how resilient the earnings are and how well-run the business is.